T&R Biofab Launches New Wound Dressing Product for Wound Protection and Scar Management

[Asia Economy Reporter Lee Gwan-ju] T&R Biofab, a company specializing in 3D bioprinting, announced on the 25th that it will launch a new wound dressing product for wound protection and scar management.

On the previous day, T&R Biofab obtained approval for a Class 2 medical device, a topical hydrogel wound dressing, from the Korea Medical Device Safety Information Center. The company plans to start sales in the domestic market once insurance notifications and related procedures are completed.

The new product is a medical device containing VdECM (vascular-derived extracellular matrix) and is used for wound protection, scar management, absorption of exudate, and prevention of bleeding, fluid loss, and contamination.

T&R Biofab extracts VdECM from porcine heart aorta, utilizing a patented special process technology that removes cells which could trigger immune responses in humans.

Unlike ordinary ECM, which is composed of over 98% collagen (with about 2% elastin), the VdECM produced contains a high amount of elastin, about 50-60%, providing moisturizing effects to the wound area and showing excellent efficacy in scar management, according to the company. As an antibiotic-free topical hydrogel wound dressing, it is safe for pediatric use and can be stored at room temperature.

Yoon Won-soo, CEO of T&R Biofab, stated, “We will begin supplying the wound dressing to domestic hospitals in the first half of this year,” adding, “As a Class 2 medical device, the approval process is relatively straightforward, allowing us to quickly expand not only in the domestic market but also overseas.”

This content was produced with the assistance of AI translation services.